

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-25. (cancelled)

26. (currently amended) A hybrid promoter comprising:

a) a peroxisome proliferator activated receptor response element (PPAR response element) comprising at least one PPAR-binding site; and

b) ~~a heterologous sequence from a promoter~~ of a IIA-1 nonpancreatic secreted phospholipase A2 (PLA2s) gene of SEQ ID NO.5 or a sequence of a PLA2s gene comprising at least residues 51 to 61, 23 to 32, 148 to 155, 5 to 170 or 51 to 170 of SEQ ID NO.5.

27. (previously presented) The hybrid promoter according to Claim 26, wherein the PPAR response element has repetition of the same binding site or a combination of different binding sites.

28. (currently amended) The hybrid promoter according to Claim 27, wherein the PPAR response element comprises one or more sites having the nucleic acid sequence of SEQ ID NO.1 ~~or a functional variant of SEQ ID NO.1.~~

29. (currently amended) The hybrid promoter according to Claim 26, wherein the PPAR response element comprises the nucleic acid sequence of SEQ ID NOS. 1, 2, 3 or 4 ~~or a functional variant of SEQ ID NOS. 1, 2, 3 or 4.~~

30. (cancelled)

31. (previously presented) The hybrid promoter according to Claim 26, wherein said functional part of the PLA2s promoter is induced by interleukin-1 β .

32-34. (cancelled)

35. (previously presented) The hybrid promoter according to Claim 26, wherein said PPAR response element is positioned 5' upstream of said sequence of said PLA2s gene comprising at least residues 51 to 61, 23 to 32, 148 to 155, 5 to 170 or 51 to 170 of SEQ ID NO.5.

36. (currently amended) The hybrid promoter according to Claim 26, comprising [[a]] an additional nucleic acid sequence that confers tissue specificity.

37. (currently amended) The hybrid promoter according to Claim 36, wherein said additional nucleic acid sequence confers specificity for chondrocytic cells.

38. (currently amended) The hybrid promoter according to Claim 36, wherein said additional nucleic acid sequence comprises SEQ ID NO:7.

39. (previously presented) An isolated nucleic acid comprising the nucleic acid sequence selected from the group consisting of SEQ ID NOS. 1, 2, 3, 4 and 5.

40. (previously presented) The isolated nucleic acid according to Claim 39, further comprising a nucleic acid sequence encoding an anti-inflammatory product.

41. (previously presented) A vector comprising a nucleic acid sequence comprising said hybrid promoter according to Claim 26.

42. (previously presented) A vector comprising a nucleic acid sequence comprising said hybrid promoter according to Claim 35.

43. (previously presented) The vector according to claim 41, wherein said vector is a plasmid.

44. (previously presented) The vector according to claim 42, wherein said vector is a plasmid.

45. (previously presented) A composition comprising (i) the isolated nucleic acid according to claim 39 and (ii) a PPAR activator.

46. (previously presented) A composition comprising (i) the vector according to claim 41 and (ii) a PPAR activator.

47. (previously presented) A composition comprising (i) the vector according to claim 42 and (ii) a PPAR activator.

48. (previously presented) A nucleic acid comprising a sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4.

49. (previously presented) A nucleic acid comprising the sequence of SEQ ID NO:6.

50. (previously presented) An isolated cell comprising the hybrid promoter according to claim 26.

51. (previously presented) An isolated cell comprising the hybrid promoter according to claim 41.

52. (previously presented) An isolated cell comprising the hybrid promoter according to claim 42.

53. (new) A hybrid promoter comprising:

a) a peroxisome proliferator activated receptor response element (PPAR response element) selected from the group consisting of SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO.4 linked to

b) a promoter of a IIA-1 nonpancreatic secreted phospholipase A2 (PLA2s) gene comprising SEQ ID NO.5 or a sequence of said PLA2s gene comprising at least residues 51 to 61, 23 to 32, 148 to 155, 5 to 170 or 51 to 170 of SEQ ID NO.5.

54. (new) The hybrid promoter according to Claim 53, wherein said peroxisome proliferator activated receptor response element (PPAR response element) is directly linked to said promoter of a IIA-1 nonpancreatic secreted phospholipase

A2 (PLA2s) gene comprising SEQ ID NO.5 or said sequence of said PLA2s gene comprising at least residues 51 to 61, 23 to 32, 148 to 155, 5 to 170 or 51 to 170 of SEQ ID NO.5.